As global markets experience varied performances, with the U.S. indices hitting record highs and Japan facing trade negotiation challenges, investors are keenly observing the shifting dynamics in Asia. Amidst these developments, penny stocks—traditionally smaller or newer companies—continue to capture attention for their potential value and growth opportunities. While the term may seem outdated, these stocks still hold relevance as they often represent companies with solid financial foundations that could offer stability and potential upside in a fluctuating market landscape.
Name |
Share Price |
Market Cap |
Financial Health Rating |
Lever Style (SEHK:1346) |
HK$1.29 |
HK$813.93M |
★★★★★★ |
Ever Sunshine Services Group (SEHK:1995) |
HK$2.08 |
HK$3.6B |
★★★★★☆ |
TK Group (Holdings) (SEHK:2283) |
HK$2.28 |
HK$1.9B |
★★★★★★ |
CNMC Goldmine Holdings (Catalist:5TP) |
SGD0.43 |
SGD174.27M |
★★★★★☆ |
Goodbaby International Holdings (SEHK:1086) |
HK$1.14 |
HK$1.9B |
★★★★★★ |
T.A.C. Consumer (SET:TACC) |
THB4.42 |
THB2.65B |
★★★★★★ |
Yangzijiang Shipbuilding (Holdings) (SGX:BS6) |
SGD2.21 |
SGD8.7B |
★★★★★☆ |
Ekarat Engineering (SET:AKR) |
THB0.92 |
THB1.35B |
★★★★★★ |
Beng Kuang Marine (SGX:BEZ) |
SGD0.20 |
SGD40.44M |
★★★★★★ |
BRC Asia (SGX:BEC) |
SGD3.16 |
SGD866.95M |
★★★★★★ |
Click here to see the full list of 993 stocks from our Asian Penny Stocks screener.
Let’s take a closer look at a couple of our picks from the screened companies.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: PSG Corporation Public Company Limited, with a market cap of THB14.79 billion, operates in turnkey engineering, procurement, and construction (EPC) and large-scale construction projects in Thailand and the Lao People’s Democratic Republic.
Operations: The company’s revenue is primarily derived from its plant and building construction segment, amounting to THB2.82 billion.
Market Cap: THB14.79B
PSG Corporation, with a market cap of THB14.79 billion, operates in the EPC and construction sectors in Thailand and Laos. Despite being debt-free and having short-term assets significantly exceeding liabilities, PSG’s earnings have declined substantially over the past year, with revenue dropping to THB642.96 million from THB1.49 billion a year ago. The company’s net profit margin has also decreased from 51.6% to 26.8%. Recent volatility in share price could be attributed to these financial results and strategic moves like the recent MOU with Electricite du Laos for renewable energy projects, potentially enhancing future growth prospects amidst current challenges.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: CSE Global Limited is an investment holding company that provides integrated industrial automation, information technology, and intelligent transport solutions across the Asia Pacific, the Americas, Europe, the Middle East, and Africa with a market cap of SGD436.54 million.
Operations: The company’s revenue is derived from three primary segments: Automation (SGD194.36 million), Communications (SGD232.04 million), and Electrification (SGD434.78 million).
Market Cap: SGD436.54M
CSE Global Limited, with a market cap of SGD436.54 million, shows a stable financial foundation with short-term assets exceeding liabilities and well-covered interest payments by EBIT. Despite experiencing a 5.4% annual decline in earnings over the past five years, recent profit growth of 16.9% signals potential recovery, outpacing industry averages. The company’s seasoned management and board add strategic depth, further enhanced by the recent appointment of Mr. Ravinder Singh as Non-Executive Director to bolster governance capabilities. However, dividend sustainability remains questionable due to insufficient free cash flow coverage despite trading below estimated fair value.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Zhejiang CONBA Pharmaceutical Co., Ltd. focuses on the research, development, production, and sales of pharmaceuticals and health products in mainland China, with a market cap of CN¥11.27 billion.
Operations: The company’s revenue primarily comes from its operations in China, totaling CN¥6.38 billion.
Market Cap: CN¥11.27B
Zhejiang CONBA Pharmaceutical Co., Ltd. demonstrates a solid financial position with short-term assets of CN¥4.5 billion surpassing both short and long-term liabilities, and its debt is well-covered by operating cash flow. Despite a slight decline in quarterly revenue to CN¥1.68 billion, the company maintains profitability with net income at CN¥189.4 million and improved profit margins from 8.1% to 9.3%. However, its return on equity remains low at 8.7%, and the board’s average tenure suggests inexperience, potentially impacting strategic decisions amidst an unstable dividend track record despite trading below estimated fair value by 16.6%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SET:PSG SGX:544 and SHSE:600572.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com